Celldex: Update Based on 2Q, 2016 Conference Call (CLDX, Neutral, $4.45)Tuesday, August 16, 2016 · 11:21 am |
|
Celldex: ACT IV Trial of Rintega in Newly Diagnosed Glioblastoma has Been Terminated (CLDX, Hold, $4.01)Monday, March 7, 2016 · 10:21 am |
|
Celldex: Meaningful Data on Two Lead Products, Rintega and glembatumumab, is not Likely Before 2017 (CLDX, Hold, $16.99)Tuesday, August 11, 2015 · 3:30 pm |
|
Celldex Pipeline Update and Investment Thesis (CLDX, Moving from Buy to Hold, $28.56)Monday, April 13, 2015 · 9:21 am |
|
Celldex, Moving to A Buy (CLDX, $14.16)Sunday, November 16, 2014 · 9:35 am |
|
Celldex: I View the Recent Data on Rindopepimut as Encouraging (CLDX, Hold, $22.52) (Subscribers Only)Friday, December 13, 2013 · 11:07 am |
|
Celldex: Equity Offering is a Positive for the Stock (CLDX, Hold, $25.88)Thursday, December 5, 2013 · 10:36 am |
|
Celldex Stay Tuned for Monday’s Conference Call on Rindopepimut (CLDX, Hold, $28.31)Friday, November 22, 2013 · 9:50 am |
|
Celldex Initiation Report: Pipeline Promise Has Been Embraced by Wall Street (CLDX, Hold, $22.79)Monday, October 21, 2013 · 12:27 pm |
|
|
There are 9 reports on file. |
